Recent Reports

Evidence report on anti-androgen drugs for high risk prostate cancer. This report will serve as the basis for discussion during a public meeting of Midwest CEPAC in September 2018.

View More on this Topic

ICER’s Draft Evidence Report, open to public comment until September 20, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

ICER

CTAF

Peanut Allergy: Research Protocol

ICER

Unsupported Price Increase Assessment: Draft Protocol

Midwest CEPAC

MS: Model Analysis Plan

ICER

Valuing A Cure: Announcement

Midwest CEPAC

Asthma: Report-at-a-Glance

New England CEPAC

DMD: Revised Scoping Document

New England CEPAC

DMD: Stakeholder List

New England CEPAC

DMD: Public Comment on Draft Scoping Document

New England CEPAC

DMD: Draft Scoping Document

CTAF

Peanut Allergy: Public Comment on Draft Scoping Document

Midwest CEPAC

Asthma: Evidence Presentation